Recent advancement of molecular mechanisms of liver fibrosis

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 22, Issue 7, 2015, Pages 512-518

  Seki, Ekihiro ^a   Brenner, David A ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alcoholic liver disease; Angiogenesis; Autophagy; Hepatic stellate cells; IL 17; IL 22; IL 33; Liver cirrhosis; Reversal; Senescence

Indexed keywords

ANTIFIBROTIC AGENT; CYTOKINE; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA;

ALCOHOL CONSUMPTION; ANGIOGENESIS; ARTICLE; AUTOIMMUNE HEPATITIS; AUTOPHAGY; CELL ACTIVATION; CELL AGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; EXTRACELLULAR MATRIX; FATTY LIVER; FIBROGENESIS; HEPATITIS B; HEPATITIS C; HUMAN; INTESTINE FLORA; LIVER FIBROSIS; MOLECULAR PATHOLOGY; MYOFIBROBLAST; NON INVASIVE MEASUREMENT; NONHUMAN; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; STELLATE CELL; ANIMAL; CELL PROLIFERATION; HEPATIC STELLATE CELL; LIVER CIRRHOSIS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RISK FACTOR;

ANIMALS; AUTOPHAGY; CELL AGING; CELL PROLIFERATION; CYTOKINES; EXTRACELLULAR MATRIX; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; MYOFIBROBLASTS; NEOVASCULARIZATION, PATHOLOGIC; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84932100243     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.245     Document Type: Article

References (62)

1. Hernandez-Gea V, Friedman SL,. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011; 6: 425-56.
2. Bataller R, Brenner DA,. Liver fibrosis. J Clin Invest. 2005; 115: 209-18.
3. Brenner DA,. Reversibility of liver fibrosis. Gastroenterology & Hepatology. 2013; 9: 737-9.
4. Seki E, Schwabe RF,. Hepatic Inflammation and Fibrosis: Functional Links and Key Pathways. Hepatology. 2015; 61: 1066-79.
5. Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ, et al., Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A. 2014; 111: E3297-305.
6. Li Y, Wang J, Asahina K,. Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial-mesenchymal transition in liver injury. Proc Natl Acad Sci U S A. 2013; 110: 2324-9.
7. Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al., Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013; 4: 2823.
8. Taura K, Miura K, Iwaisako K, Osterreicher CH, Kodama Y, Penz-Osterreicher M, et al., Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology. 2010; 51: 1027-36.
9. Scholten D, Weiskirchen R,. Questioning the challenging role of epithelial-to-mesenchymal transition in liver injury. Hepatology. 2011; 53: 1048-51.
10. Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, Alpini G, et al., Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology. 2011; 53: 1685-95.
11. Schnabl B, Brenner DA,. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014; 146: 1513-24.
12. Seki E, Schnabl B,. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 2012; 590: 447-58.
13. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al., TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007; 13: 1324-32.
14. Liu C, Chen X, Yang L, Kisseleva T, Brenner DA, Seki E,. Transcriptional repression of the transforming growth factor beta (TGF-beta) Pseudoreceptor BMP and activin membrane-bound inhibitor (BAMBI) by Nuclear Factor kappaB (NF-kappaB) p50 enhances TGF-beta signaling in hepatic stellate cells. J Biol Chem. 2014; 289: 7082-91.
15. Zhu Q, Zou L, Jagavelu K, Simonetto DA, Huebert RC, Jiang ZD, et al., Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol. 2012; 56: 893-9.
16. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, et al., Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2011; 53: 209-18.
17. Huang H, Shiffman ML, Friedman S, Venkatesh R, Bzowej N, Abar OT, et al., A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology. 2007; 46: 297-306.
18. Hartmann P, Haimerl M, Mazagova M, Brenner DA, Schnabl B,. Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. Gastroenterology. 2012; 143: 1330-40 e1331.
19. Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B,. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol. 2012; 56: 1283-92.
20. De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, et al., Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 2014; 59: 1738-49.
21. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, et al., Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013; 499: 97-101.
22. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, et al., Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012; 21: 504-16.
23. Mazagova M, Wang L, Anfora AT, Wissmueller M, Lesley SA, Miyamoto Y, et al., Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J. 2015; 29: 1043-55.
24. Hammerich L, Heymann F, Tacke F,. Role of IL-17 and Th17 cells in liver diseases. Clin Dev Immunol. 2011; 2011: 345803.
25. Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, et al., Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology. 2012; 143: 765-776 e761-3.
26. Guillot A, Hamdaoui N, Bizy A, Zoltani K, Souktani R, Zafrani ES, et al., Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver. Hepatology. 2014; 59: 296-306.
27. Cobleigh MA, Robek MD,. Protective and pathological properties of IL-22 in liver disease: implications for viral hepatitis. Am J Pathol. 2013; 182: 21-8.
28. Kronenberger B, Rudloff I, Bachmann M, Brunner F, Kapper L, Filmann N, et al., Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study. BMC Med. 2012; 10: 102.
29. Jiang R, Tan Z, Deng L, Chen Y, Xia Y, Gao Y, et al., Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology. 2011; 54: 900-9.
30. Radaeva S, Sun R, Pan HN, Hong F, Gao B,. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology. 2004; 39: 1332-42.
31. Ki SH, Park O, Zheng M, Morales-Ibanez O, Kolls JK, Bataller R, et al., Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology. 2010; 52: 1291-1300.
32. Feng D, Wang Y, Wang H, Weng H, Kong X, Martin-Murphy BV, et al., Acute and chronic effects of IL-22 on acetaminophen-induced liver injury. J Immunol. 2014; 193: 2512-18.
33. Kong X, Feng D, Wang H, Hong F, Bertola A, Wang FS, et al., Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology. 2012; 56: 1150-9.
34. Zhao J, Zhang Z, Luan Y, Zou Z, Sun Y, Li Y, et al., Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology. 2014; 59: 1331-42.
35. Zhang Y, Cobleigh MA, Lian JQ, Huang CX, Booth CJ, Bai XF, et al., A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology. 2011; 141: 1897-906.
36. Feng D, Kong X, Weng H, Park O, Wang H, Dooley S, et al., Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology. 2012; 143: 188-98 e187.
37. McHedlidze T, Waldner M, Zopf S, Walker J, Rankin AL, Schuchmann M, et al., Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity. 2013; 39: 357-71.
38. Sun Y, Zhang JY, Lv S, Wang H, Gong M, Du N, et al., Interleukin-33 promotes disease progression in patients with primary biliary cirrhosis. Tohoku J Exp Med. 2014; 234: 255-61.
39. Li J, Razumilava N, Gores GJ, Walters S, Mizuochi T, Mourya R, et al., Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest. 2014; 124: 3241-51.
40. Dooley S, ten Dijke P,. TGF-beta in progression of liver disease. Cell Tissue Res. 2012; 347: 245-56.
41. Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, et al., Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013; 19: 1617-24.
42. Yan X, Lin Z, Chen F, Zhao X, Chen H, Ning Y, et al., Human BAMBI cooperates with Smad7 to inhibit transforming growth factor-beta signaling. J Biol Chem. 2009; 284: 30097-104.
43. Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, et al., A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell. 2013; 153: 601-13.
44. Yang L, Kwon J, Popov Y, Gajdos GB, Ordog T, Brekken RA, et al., Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology. 2014; 146: 1339-50 e1331.
45. Weng HL, Ciuclan L, Liu Y, Hamzavi J, Godoy P, Gaitantzi H, et al., Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes. Hepatology. 2007; 46: 1257-70.
46. Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner D,. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology. 2003; 37: 653-64.
47. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, et al., Senescence of activated stellate cells limits liver fibrosis. Cell. 2008; 134: 657-67.
48. Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, et al., Non-cell-autonomous tumor suppression by p53. Cell. 2013; 153: 449-60.
49. Hernandez-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, Yue Z, et al., Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology. 2012; 142: 938-46.
50. Kaushal S, Annamali M, Blomenkamp K, Rudnick D, Halloran D, Brunt EM, et al., Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. Exp Biol Med. 2010; 235: 700-9.
51. Hidvegi T, Ewing M, Hale P, Dippold C, Beckett C, Kemp C, et al., An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science. 2010; 329: 229-32.
52. Rockey DC,. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis. 2001; 21: 337-49.
53. Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E, et al., Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology. 2005; 42: 1339-48.
54. Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher CH, et al., Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology. 2008; 135: 1729-38.
55. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, et al., Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut. 2003; 52: 1347-54.
56. Ding BS, Cao Z, Lis R, Nolan DJ, Guo P, Simons M, et al., Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature. 2014; 505: 97-102.
57. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, et al., Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 1998; 102: 538-49.
58. She H, Xiong S, Hazra S, Tsukamoto H,. Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem. 2005; 280: 4959-67.
59. Troeger JS, Mederacke I, Gwak GY, Dapito DH, Mu X, Hsu CC, et al., Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology. 2012; 143: 1073-1083 e1022.
60. Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, et al., Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A. 2012; 109: 9448-53.
61. Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, Ali A, et al., Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A. 2012; 109: E3186-95.
62. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al., Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015; 385: 956-65.